Zdrowie i gospodarka · 17/09/2021
FDA Requests Public Comment on Biosimilars User Fee Program Information Collection
The Food and Drug Administration is seeking public input on a proposed information collection related to its Biosimilars User Fee Program, as required by the Paperwork Reduction Act of 1995.
Source: Federal Register — Food and Drug AdministrationOpen original release →